In recent years, considerable progress has been made in the biochemical, morphological and molecular genetic differentiation of congenital hyperinsulinism (CHI). Fluorine-18 L-3,4-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) has been introduced for differentiation between focal and diffuse CHI. The ability to take up L-DOPA and convert it into dopamine is correlated with the activity of the aromatic amino acid decarboxylase and increased in the hyperfunctional affected pancreatic area in comparison to normally functioning pancreas. The high sensitivity of this method allows the surgeon to perform a curative limited resection of a focus without the risk of long-term diabetes. The exact preoperative planning by 18F-DOPA-PET/CT computer tomography allows laparoscopic operation in selected cases with the focus in the tail and limits necessity to open the pancreatic duct in cases with focus in the head. Patients with persistent CHI should be managed within a strong network of diagnostic, treatment, and research institutions.

Keywords:
[18F]-DOPA-PET/CT, L-DOPA, Congenital hyperinsulinism, Positron emission tomography, Computer tomography
1.
Hussain K: Congenital hyperinsulinism. Semin Fetal Neonatal Med 2005;10:369–376.
2.
De Lonlay P, Giurgea I, Touati G, Saudubray JM: Neonatal hypoglycaemia: aetiologies. Semin Neonatol 2004;9:49–58.
3.
Dekelbab BH, Sperling MA: Hyperinsulinemic hypoglycemia of infancy: the challenge continues. Diabetes Metab Res Rev 2004;20:189–195.
4.
Jack MM, Greer RM, Thomsett MJ, Walker RM, Bell JR, Choong C, Cowley DM, Herington AC, Cotterill AM: The outcome in Australian children with hyperinsulinism of infancy: early extensive surgery in severe cases lowers risk of diabetes. Clin Endocrinol (Oxf) 2003;58:355–364.
5.
Glaser B, Landau H, Permutt MA: Neonatal hyperinsulinism. Trends Endocrinol Metab 1999;10:55–61.
6.
Hussain K: Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy. Horm Res 2008;69:2–13.
7.
Palladino AA, Bennett MJ, Stanley CA: Hyperinsulinism in infancy and childhood: when an insulin level is not always enough. Clin Chem 2008;54:256–263.
8.
De Leon DD, Stanley CA: Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab 2007;3:57–68.
9.
Delonlay P, Simon A, Galmiche-Rolland L, Giurgea I, Verkarre V, Aigrain Y, Santiago-Ribeiro MJ, Polak M, Robert JJ, Bellanne-Chantelot C, Brunelle F, Nihoul-Fekete C, Jaubert F: Neonatal hyperinsulinism: clinicopathologic correlation. Hum Pathol 2007;38:387–399.
10.
Barthlen W, Blankenstein O, Mau H, Koch M, Hohne C, Mohnike W, Eberhard T, Fuechtner F, Lorenz-Depiereux B, Mohnike K: Evaluation of [18F]DOPA PET-CT for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab 2008;93:869–875.
11.
Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R, Zhuang H, MacMullen C, Becker S, Adzick NS, Divgi C, Alavi A, Stanley CA: Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab 2007;92:4706–4711.
12.
Ashcroft FM: The Walter B. Cannon Physiology in Perspective Lecture, 2007. ATP-sensitive K+ channels and disease: from molecule to malady. Am J Physiol 2007;293:E880–E889.
13.
Hussain K: Insights in congenital hyperinsulinism. Endocr Dev 2007;11:106–121.
14.
Lin YW, Bushman JD, Yan FF, Haidar S, MacMullen C, Ganguly A, Stanley CA, Shyng SL: Destabilization of ATP-sensitive potassium channel activity by novel KCNJ11 mutations identified in congenital hyperinsulinism. J Biol Chem 2008;283:9146–9156.
15.
Rahier J, Guiot Y, Sempoux C: Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis. Arch Dis Child Fetal Neonatal Ed 2000;82:F108–F112.
16.
Sempoux C, Guiot Y, Jaubert F, Rahier J: Focal and diffuse forms of congenital hyperinsulinism: the keys for differential diagnosis. Endocr Pathol 2004;15:241–246.
17.
Al Nassar S, Sakati N, Al Ashwal A, Bin-Abbas B: Persistent hyperinsulinaemic hypoglycaemia of infancy in 43 children: long-term clinical and surgical follow-up. Asian J Surg 2006;29:207–211.
18.
Cherian MP, Abduljabbar MA: Persistent hyperinsulinemic hypoglycemia of infancy: long-term outcome following 95% pancreatectomy. J Pediatr Endocrinol Metab 2005;18:1441–1448.
19.
De Lonlay P, Fournet JC, Touati G, Groos MS, Martin D, Sevin C, Delagne V, Mayaud C, Chigot V, Sempoux C, Brusset MC, Laborde K, Bellane-Chantelot C, Vassault A, Rahier J, Junien C, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ: Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. Eur J Pediatr 2002;161:37–48.
20.
Filan PM, Inder TE, Cameron FJ, Kean MJ, Hunt RW: Neonatal hypoglycemia and occipital cerebral injury. J Pediatr 2006;148:552–555.
21.
Mazor-Aronovitch K, Gillis D, Lobel D, Hirsch HJ, Pinhas-Hamiel O, Modan-Moses D, Glaser B, Landau H: Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism. Eur J Endocrinol 2007;157:491–497.
22.
Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E: Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 2003;149:43–51.
23.
Steinkrauss L, Lipman TH, Hendell CD, Gerdes M, Thornton PS, Stanley CA: Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism. J Pediatr Nurs 2005;20:109–118.
24.
Bougneres PF, Landier F, Garnier P, Job JC, Chaussain JL: Treatment of insulin excess by continuous subcutaneous infusion of somatostatin and glucagon in an infant. J Pediatr 1985;106:792–794.
25.
Glaser B, Hirsch HJ, Landau H: Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr 1993;123:644–650.
26.
Lindley K, Knafelz D, St Louis D, Dunne M, Aynsley-Green A, Milla PJ: Surface electrogastrographic evidence of foregut dysmotility in persistent hyperinsulinaemic hypoglycaemia of infancy (abstract). J Physiol 1997;499:108.
27.
Touati G, Poggi-Travert F, Ogier DB, Rahier J, Brunelle F, Nihoul-Fekete C, Czernichow P, Saudubray JM: Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. Eur J Pediatr 1998;157:628–633.
28.
Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA: Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637–643.
29.
Plecko B, Stoeckler-Ipsiroglu S, Schober E, Harrer G, Mlynarik V, Gruber S, Moser E, Moeslinger D, Silgoner H, Ipsiroglu O: Oral β-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of β-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy. Pediatr Res 2002;52:301–306.
30.
Muller D, Zimmering M, Roehr CC: Should nifedipine be used to counter low blood sugar levels in children with persistent hyperinsulinaemic hypoglycaemia? Arch Dis Child 2004;89:83–85.
31.
Katz LE, Ferry RJ Jr, Stanley CA, Collett-Solberg PF, Baker L, Cohen P: Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective β-cell sulfonylurea receptor. J Clin Endocrinol Metab 1999;84:3117–3124.
32.
Hussain K, Aynsley-Green A, Stanley CA: Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy. Pediatr Endocrinol Rev 2004;2(suppl 1):163–167.
33.
Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fekete C, Lonlay-Debeney P, Brunelle F, Otonkoski T, Thornton P, Lindley KJ: Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 2000;82:F98–F107.
34.
Mohnike K, Blankenstein O, Pfutzner A, Poetzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM: Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 2008 (accepted).
35.
Suchi M, Thornton PS, Adzick NS, MacMullen C, Ganguly A, Stanley CA, Ruchelli ED: Congenital hyperinsulinism: intraoperative biopsy interpretation can direct the extent of pancreatectomy. Am J Surg Pathol 2004;28:1326–1335.
36.
Lovvorn HN III, Nance ML, Ferry RJ Jr, Stolte L, Baker L, O’Neill JA Jr, Schnaufer L, Stanley CA, Adzick NS: Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. J Pediatr Surg 1999;34:786–792.
37.
Sperling MA: PET scanning for infants with HHI: a small step for affected infants, a giant leap for the field. J Pediatr 2007;150:122–124.
38.
Giurgea I, Sempoux C, Bellanne-Chantelot C, Ribeiro M, Hubert L, Boddaert N, Saudubray JM, Robert JJ, Brunelle F, Rahier J, Jaubert F, Nihoul-Fekete C, de Lonlay P: The Knudson’s two-hit model and timing of somatic mutation may account for the phenotypic diversity of focal congenital hyperinsulinism. J Clin Endocrinol Metab 2006;91:4118–4123.
39.
Hussain K, Seppanen M, Nanto-Salonen K, Adzick NS, Stanley CA, Thornton P, Minn H: The diagnosis of ectopic focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. J Clin Endocrinol Metab 2006;91:2839–2842.
40.
Peranteau WH, Bathaii SM, Pawel B, Hardy O, Alavi A, Stanley CA, Adzick NS: Multiple ectopic lesions of focal islet adenomatosis identified by positron emission tomography scan in an infant with congenital hyperinsulinism. J Pediatr Surg 2007;42:188–192.
41.
Fekete CN, de Lonlay P, Jaubert F, Rahier J, Brunelle F, Saudubray JM: The surgical management of congenital hyperinsulinemic hypoglycemia in infancy. J Pediatr Surg 2004;39:267–269.
42.
Brunelle F, Negre V, Barth MO, Fekete CN, Czernichow P, Saudubray JM, Kuntz F, Tach T, L’Allemand D: Pancreatic venous samplings in infants and children with primary hyperinsulinism. Pediatr Radiol 1989;19:100–103.
43.
Dubois J, Brunelle F, Touati G, Sebag G, Nuttin C, Thach T, Nikoul-Fekete C, Rahier J, Saudubray JM: Hyperinsulinism in children: diagnostic value of pancreatic venous sampling correlated with clinical, pathological and surgical outcome in 25 cases. Pediatr Radiol 1995;25:512–516.
44.
Chigot V, de Lonlay P, Nassogne MC, Laborde K, Delagne V, Fournet JC, Nihoul-Fekete C, Saudubray JM, Brunelle F: Pancreatic arterial calcium stimulation in the diagnosis and localisation of persistent hyperinsulinemic hypoglycaemia of infancy. Pediatr Radiol 2001;31:650–655.
45.
Giurgea I, Laborde K, Touati G, Bellanne-Chantelot C, Nassogne MC, Sempoux C, Jaubert F, Khoa N, Chigot V, Rahier J, Brunelle F, Nihoul-Fekete C, Dunne MJ, Stanley C, Saudubray JM, Robert JJ, de Lonlay P: Acute insulin responses to calcium and tolbutamide do not differentiate focal from diffuse congenital hyperinsulinism. J Clin Endocrinol Metab 2004;89:925–929.
46.
Stanley CA, Thornton PS, Ganguly A, MacMullen C, Underwood P, Bhatia P, Steinkrauss L, Wanner L, Kaye R, Ruchelli E, Suchi M, Adzick NS: Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic arterial calcium stimulation. J Clin Endocrinol Metab 2004;89:288–296.
47.
Adzick NS, Thornton PS, Stanley CA, Kaye RD, Ruchelli E: A multidisciplinary approach to the focal form of congenital hyperinsulinism leads to successful treatment by partial pancreatectomy. J Pediatr Surg 2004;39:270–275.
48.
Otonkoski T, Veijola R, Huopio H, Nanto-Salonen K, Tapanainen P, De Lonlay J, Fekete C, Brunelle F, Minn H, Nuutila P: Diagnosis of focal persistent hyperinsulinism of infancy with 18F-fluoro-L-L-DOPA PET. Horm Res 2003;60(suppl 2):2.
49.
Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B, Oberg K: Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333–337.
50.
Hoegerle S, Schneider B, Kraft A, Moser E, Nitzsche EU: Imaging of a metastatic gastrointestinal carcinoid by 18F-DOPA positron emission tomography. Nuklearmedizin 1999;38:127–130.
51.
Fuchtner F, Zessin J, Mading P, Wust F: Aspects of 6-[18F]fluoro-L-DOPA preparation. Deuterochloroform as a substitute solvent for Freon 11. Nuklearmedizin 2008;47:62–64.
52.
Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG: Expression of neuroendocrine cell markers L-DOPA decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 1988;48:4078–4082.
53.
Lindstrom P: Aromatic L-amino-acid decarboxylase activity in mouse pancreatic islets. Biochim Biophys Acta 1986;884:276–281.
54.
Rubi B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, Maechler P: Dopamine D2-like receptors are expressed in pancreatic β cells and mediate inhibition of insulin secretion. J Biol Chem 2005;280:36824–36832.
55.
Whone AL, Bailey DL, Remy P, Pavese N, Brooks DJ: A technique for standardized central analysis of 6-18F-fluoro-L-DOPA PET data from a multicenter study. J Nucl Med 2004;45:1135–1145.
56.
De Lonlay P, Simon-Carre A, Ribeiro MJ, Boddaert N, Giurgea I, Laborde K, Bellanne-Chantelot C, Verkarre V, Polak M, Rahier J, Syrota A, Seidenwurm D, Nihoul-Fekete C, Robert JJ, Brunelle F, Jaubert F: Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J Clin Endocrinol Metab 2006;91:933–940.
57.
Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K: Imaging of advanced neuroendocrine tumors with 18F-FDOPA PET. J Nucl Med 2004;45:1161–1167.
58.
Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL: Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728–734.
59.
Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Hojgaard L, Kristjansen PE: How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 2006;33:697–702.
60.
Otonkoski T, Nanto-Salonen K, Seppanen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekstrom K, Guiot Y, Rahier J, Laakso M, Rintala R, Nuutila P, Minn H: Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 2006;55:13–18.
61.
Hardy OT, Hernandez-Pampaloni M, Saffer JR, Suchi M, Ruchelli E, Zhuang H, Ganguly A, Freifelder R, Adzick NS, Alavi A, Stanley CA: Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr 2007;150:140–145.
62.
Mohnike K, Blankenstein O, Christesen HT, De Lonlay J, Hussain K, Koopmans KP, Minn H, Mohnike W, Mutair A, Otonkoski T, Rahier J, Ribeiro M, Schoenle E, Fekete CN: Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res 2006;66:40–42.
63.
Ribeiro MJ, Boddaert N, Bellanne-Chantelot C, Bourgeois S, Valayannopoulos V, Delzescaux T, Jaubert F, Nihoul-Fekete C, Brunelle F, de Lonlay P: The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging 2007;34:2120–2128.
64.
Kauhanen S, Seppanen M, Minn H, Gullichsen R, Salonen A, Alanen K, Parkkola R, Solin O, Bergman J, Sane T, Salmi J, Valimaki M, Nuutila P: Fluorine-18-L-dihydroxyphenylalanine positron emission tomography as a tool to localize an insulinoma or β-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007;92:1237–1244.
65.
Kapoor RR, Gilbert C, Mohnike K, Blankenstein O, Fuechtner F, Hussain K: Congenital hyperinsulinism: [18F]DOPA PET/CT scan of a focal lesion in the head of the pancreas. Arch Dis Child Fetal Neonatal Ed 2008;93:F166.
66.
Minn H, Leskinen-Kallio S, Lindholm P, Bergman J, Ruotsalainen U, Teras M, Haaparanta M: [18F]fluorodeoxyglucose uptake in tumors: kinetic versus steady-state methods with reference to plasma insulin. J Comput Assist Tomogr 1993;17:115–123.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.